SI0968208T1 - Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia - Google Patents

Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia

Info

Publication number
SI0968208T1
SI0968208T1 SI9830477T SI9830477T SI0968208T1 SI 0968208 T1 SI0968208 T1 SI 0968208T1 SI 9830477 T SI9830477 T SI 9830477T SI 9830477 T SI9830477 T SI 9830477T SI 0968208 T1 SI0968208 T1 SI 0968208T1
Authority
SI
Slovenia
Prior art keywords
quinoline
therapy
treatment
compounds useful
benign prostatic
Prior art date
Application number
SI9830477T
Other languages
English (en)
Slovenian (sl)
Inventor
David Nathan Abraham Pfizer Central Res. Fox
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SI0968208T1 publication Critical patent/SI0968208T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9830477T 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia SI0968208T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9700504.5A GB9700504D0 (en) 1997-01-11 1997-01-11 Pharmaceutical compounds
PCT/EP1998/000143 WO1998030560A1 (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia
EP98904058A EP0968208B1 (de) 1997-01-11 1998-01-06 Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie

Publications (1)

Publication Number Publication Date
SI0968208T1 true SI0968208T1 (en) 2003-10-31

Family

ID=10805838

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830477T SI0968208T1 (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia

Country Status (45)

Country Link
US (4) US6169093B1 (de)
EP (1) EP0968208B1 (de)
JP (1) JP3357677B2 (de)
KR (1) KR100347472B1 (de)
CN (2) CN1093858C (de)
AP (1) AP819A (de)
AR (1) AR010396A1 (de)
AT (1) ATE242238T1 (de)
AU (1) AU724990B2 (de)
BG (1) BG63918B1 (de)
BR (1) BR9807068A (de)
CA (1) CA2277473C (de)
CZ (1) CZ295580B6 (de)
DE (1) DE69815313T2 (de)
DK (1) DK0968208T3 (de)
DZ (1) DZ2394A1 (de)
EA (1) EA002851B1 (de)
ES (1) ES2198695T3 (de)
GB (1) GB9700504D0 (de)
HK (2) HK1025327A1 (de)
HN (1) HN1998000002A (de)
HR (1) HRP980010B1 (de)
HU (1) HUP0000942A3 (de)
ID (1) ID21863A (de)
IL (1) IL130762A (de)
IS (1) IS2012B (de)
MA (1) MA26465A1 (de)
MY (1) MY119623A (de)
NO (1) NO318609B1 (de)
NZ (1) NZ336302A (de)
OA (1) OA11074A (de)
PA (1) PA8444301A1 (de)
PE (1) PE44499A1 (de)
PL (1) PL334678A1 (de)
PT (1) PT968208E (de)
SA (1) SA97180705B1 (de)
SI (1) SI0968208T1 (de)
SK (1) SK284779B6 (de)
TN (1) TNSN98004A1 (de)
TR (1) TR199901604T2 (de)
TW (1) TW444013B (de)
UA (1) UA62945C2 (de)
WO (1) WO1998030560A1 (de)
YU (1) YU31699A (de)
ZA (1) ZA98166B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
OA12186A (en) 2000-03-03 2006-05-09 Pfizer 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs.
BR0113585A (pt) 2000-08-31 2003-07-29 Hoffmann La Roche Derivados quinazolina como antagonistas adrenérgicos alfa-1
CN1237060C (zh) * 2001-01-02 2006-01-18 弗·哈夫曼-拉罗切有限公司 用作α1A/B肾上腺素能受体拮抗剂的喹唑酮衍生物
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
GB0112061D0 (en) * 2001-05-18 2001-07-11 Pfizer Ltd Process for the production of quinazolines
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
ATE386741T1 (de) 2002-09-26 2008-03-15 Pfizer Pyrazolamide zur behandlung von hiv-infektionen
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
RU2331438C2 (ru) 2002-12-13 2008-08-20 Уорнер-Ламберт Компани Ллс Альфа-2-дельта лиганд для лечения симптомов нижних мочевыводящих путей
AU2004255585A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
WO2005089804A2 (en) * 2004-03-16 2005-09-29 Pfizer Limited Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
WO2008084493A2 (en) * 2007-01-09 2008-07-17 Unichem Laboratories Limited A novel process for the preparation of 2-halo-4-aminoquinazolines
JP2009126784A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法。
JP2009126785A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
RU2695815C9 (ru) * 2014-03-24 2019-10-28 Гуандун Чжуншэн Фармасьютикал Ко., Лтд Хинолиновые производные в качестве ингибиторов smo

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875506A (en) * 1907-03-19 1907-12-31 Berry H Collins Guiding attachment for penholders.
GB1390014A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv Process for the preparation of carbocyclic fused pyrimidine derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
GB9526546D0 (en) 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
AP819A (en) 2000-04-03
AU724990B2 (en) 2000-10-05
CN1243513A (zh) 2000-02-02
TNSN98004A1 (fr) 2005-03-15
UA62945C2 (en) 2004-01-15
PT968208E (pt) 2003-09-30
US20030130259A1 (en) 2003-07-10
SK90799A3 (en) 2001-03-12
IS5093A (is) 1999-06-25
KR20000070022A (ko) 2000-11-25
CZ9902436A3 (cs) 2000-10-11
HK1054389A1 (en) 2003-11-28
AU6208898A (en) 1998-08-03
IS2012B (is) 2005-05-13
PA8444301A1 (es) 2000-05-24
CN1191249C (zh) 2005-03-02
US6521629B2 (en) 2003-02-18
TW444013B (en) 2001-07-01
HUP0000942A2 (hu) 2001-04-28
IL130762A0 (en) 2001-01-28
OA11074A (en) 2002-03-13
EP0968208B1 (de) 2003-06-04
HN1998000002A (es) 1999-01-08
YU31699A (sh) 2001-07-10
JP3357677B2 (ja) 2002-12-16
WO1998030560A1 (en) 1998-07-16
SK284779B6 (sk) 2005-11-03
BG103560A (en) 2000-06-30
GB9700504D0 (en) 1997-02-26
DE69815313T2 (de) 2003-12-11
EA199900531A1 (ru) 2000-02-28
US6169093B1 (en) 2001-01-02
CA2277473C (en) 2003-08-12
EP0968208A1 (de) 2000-01-05
JP2000507966A (ja) 2000-06-27
NO993396D0 (no) 1999-07-09
BG63918B1 (bg) 2003-06-30
DE69815313D1 (de) 2003-07-10
NO993396L (no) 1999-07-09
CA2277473A1 (en) 1998-07-16
CN1093858C (zh) 2002-11-06
NO318609B1 (no) 2005-04-18
DZ2394A1 (fr) 2003-06-04
US6365599B1 (en) 2002-04-02
US20020040028A1 (en) 2002-04-04
EA002851B1 (ru) 2002-10-31
BR9807068A (pt) 2000-05-02
ZA98166B (en) 1999-07-09
KR100347472B1 (ko) 2002-08-07
PE44499A1 (es) 1999-05-06
ES2198695T3 (es) 2004-02-01
HK1025327A1 (en) 2000-11-10
HRP980010A2 (en) 1998-10-31
TR199901604T2 (xx) 1999-12-21
HK1054389B (zh) 2005-10-14
CZ295580B6 (cs) 2005-08-17
MA26465A1 (fr) 2004-12-20
HRP980010B1 (en) 2002-06-30
SA97180705B1 (ar) 2005-12-26
PL334678A1 (en) 2000-03-13
IL130762A (en) 2005-12-18
AR010396A1 (es) 2000-06-07
ID21863A (id) 1999-08-05
HUP0000942A3 (en) 2002-06-28
NZ336302A (en) 2000-08-25
US6653302B2 (en) 2003-11-25
CN1403453A (zh) 2003-03-19
DK0968208T3 (da) 2003-07-28
MY119623A (en) 2005-06-30
AP9801175A0 (en) 1998-01-31
ATE242238T1 (de) 2003-06-15

Similar Documents

Publication Publication Date Title
SI0968208T1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
ZA9610784B (en) Quinoline and quinazoline compounds useful in therapy.
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU1657097A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
EP0855910A4 (de) Verwendbare konjugate zur behandlung der gutartigen prostatehyperplasie
ZA983968B (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia.
ZA982819B (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
HK1030776A1 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
AU6570998A (en) Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
EP0748627A3 (de) Melatoninagonisten zur Behandlung von gutartigen Hyperplasieformen der Prostata
EP1435913A4 (de) Verfahren zur behandlung der benignen prostatahyperplasie und anderer gutartiger erkrankungen der prostata
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU2003204320A1 (en) Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
AU2002300904A1 (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
SI0925069T1 (sl) Uporaba Cetrorelix-a za zdravljenje benigne hipertrofije prostate in prostatnega raka
ZA988293B (en) Compositions and methods for the treatment of tumor.
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia